Considering our findings, trametinib, which is already approved for BRAF-mutated melanoma, can greatly potentiate the induction of HLA-I protein expression and, thus, might be a candidate for further clinical study in HCC with the addition of an ICI. The gene discussed is BRAF; the disease is melanoma.